{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:47:37Z","timestamp":1782510457158,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jval.2026.02.001","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:34:09Z","timestamp":1771605249000},"page":"1162-1170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Curcumin-QingDai Combination for Active Ulcerative Colitis: A Cost-Effectiveness Analysis"],"prefix":"10.1016","volume":"29","author":[{"given":"Henit","family":"Yanai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Loebstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Leshno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2026.02.001_bib1","first-page":"117","article-title":"Disease burden and unmet medical needs in patients with ulcerative colitis in Greece: a cross-sectional patient survey","volume":"13","author":"Gourzoulidis","year":"2025","journal-title":"Med Sci (Basel)"},{"issue":"3","key":"10.1016\/j.jval.2026.02.001_bib2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","article-title":"Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases","volume":"22","author":"Mikocka-Walus","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.jval.2026.02.001_bib3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2016.10.036","article-title":"Etiology and treatment of pain and psychosocial issues in patients with inflammatory bowel diseases","volume":"152","author":"Regueiro","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jval.2026.02.001_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10.1016\/j.jval.2026.02.001_bib5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jval.2026.02.001_bib6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jval.2026.02.001_bib7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.16445","article-title":"Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents","volume":"54","author":"van Linschoten","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jval.2026.02.001_bib8","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/MCG.0000000000001416","article-title":"Novel bioenhanced curcumin with mesalamine for induction of clinical and endoscopic remission in mild-to-moderate ulcerative colitis: a randomized double-blind placebo-controlled pilot study","volume":"55","author":"Banerjee","year":"2021","journal-title":"J Clin Gastroenterol"},{"issue":"12","key":"10.1016\/j.jval.2026.02.001_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.cgh.2006.08.008","article-title":"Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial","volume":"4","author":"Hanai","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.jval.2026.02.001_bib10","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.cgh.2015.02.019","article-title":"Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial","volume":"13","author":"Lang","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jval.2026.02.001_bib11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1053\/j.gastro.2017.11.024","article-title":"Efficacy of indigo Naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis","volume":"154","author":"Naganuma","year":"2018","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jval.2026.02.001_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1159\/000526646","article-title":"Curcumin-QingDai combination as treatment for moderate-severe ulcerative colitis","volume":"16","author":"Ben-Horin","year":"2022","journal-title":"Case Rep Gastroenterol"},{"issue":"2","key":"10.1016\/j.jval.2026.02.001_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/apt.17538","article-title":"Real-world experience with curcumin-QingDai combination for patients with active ulcerative colitis: a retrospective multicentre cohort study","volume":"58","author":"Yanai","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jval.2026.02.001_bib14","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1093\/ibd\/izad072","article-title":"Attitudes toward Integrative Medicine in inflammatory bowel disease: a survey among Israeli inflammatory bowel disease experts","volume":"29","author":"Zittan","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.jval.2026.02.001_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cgh.2023.05.023","article-title":"Curcumin-QingDai combination for patients with active ulcerative colitis: a randomized, double-blinded, placebo-controlled trial","volume":"22","author":"Ben-Horin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jval.2026.02.001_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae147","article-title":"Change in bowel urgency in active ulcerative colitis patients treated with curcumin-QingDai (CurQD): a post-hoc analysis of a randomized placebo-controlled trial","volume":"19","author":"Ben-Horin","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2026.02.001_bib17","first-page":"s18","article-title":"Clinical biochemical and intestinal ultrasonography response to curcumin-Qingdai (CurQD) combination in pediatric patients with inflammatory bowel disease: a cases series","volume":"30","author":"Chavannes","year":"2023","journal-title":"Inflam Bowel Dis"},{"key":"10.1016\/j.jval.2026.02.001_bib18","author":"Gencarelli"},{"issue":"1","key":"10.1016\/j.jval.2026.02.001_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00384-023-04397-7","article-title":"Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany","volume":"38","author":"Bokemeyer","year":"2023","journal-title":"Int J Colorectal Dis"},{"issue":"5","key":"10.1016\/j.jval.2026.02.001_bib20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/03007995.2023.2194782","article-title":"The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom","volume":"39","author":"Lindsay","year":"2023","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.jval.2026.02.001_bib21","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/apt.17092","article-title":"Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix","volume":"56","author":"Atia","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jval.2026.02.001_bib22","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","article-title":"Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population","volume":"10","author":"Ha","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jval.2026.02.001_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/10543406.2010.544437","article-title":"Average cost-effectiveness ratio with censored data","volume":"22","author":"Bang","year":"2012","journal-title":"J Biopharm Stat"},{"issue":"1","key":"10.1016\/j.jval.2026.02.001_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.14309\/ajg.0000000000000847","article-title":"Cost-effectiveness of 5-aminosalicylate therapy in combination with biologics or tofacitinib in the treatment of ulcerative colitis","volume":"116","author":"Shaffer","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jval.2026.02.001_bib25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s41669-022-00331-9","article-title":"Cost effectiveness of subcutaneous vedolizumab for maintenance treatment of ulcerative colitis in Canada","volume":"6","author":"Fenu","year":"2022","journal-title":"Pharmacoecon Open"},{"issue":"6","key":"10.1016\/j.jval.2026.02.001_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s41669-022-00360-4","article-title":"Cost effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Colombia","volume":"6","author":"Gil","year":"2022","journal-title":"Pharmacoecon Open"},{"issue":"5","key":"10.1016\/j.jval.2026.02.001_bib27","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40273-023-01254-x","article-title":"Cost-effectiveness analysis of tofacitinib compared with biologics in biologic-naive patients with moderate-to-severe ulcerative colitis in Japan","volume":"41","author":"Kobayashi","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.jval.2026.02.001_bib28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jval.2026.02.001_bib29","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/ibd\/izac160","article-title":"Cost-effectiveness analysis of subcutaneous infliximab for inflammatory bowel diseases in sequential biologic treatment","volume":"29","author":"Bouhnik","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.jval.2026.02.001_bib30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/apt.17261","article-title":"Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis","volume":"57","author":"Cortesi","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jval.2026.02.001_bib31","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2020.05.010","article-title":"Microsimulation model to determine the cost-effectiveness of Treat-to-target strategies for ulcerative colitis","volume":"19","author":"Dulai","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5S","key":"10.1016\/j.jval.2026.02.001_bib32","article-title":"Cost-effectiveness of universal routine sonographic cervical-length measurement at 19 to 25 weeks gestation","volume":"6","author":"Leshno","year":"2024","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"3","key":"10.1016\/j.jval.2026.02.001_bib33","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1634\/theoncologist.2018-0656","article-title":"A cost-effectiveness analysis of nivolumab and ipilimumab versus sunitinib in first-line intermediate- to poor-risk advanced renal cell carcinoma","volume":"24","author":"Reinhorn","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jval.2026.02.001_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/14737167.2021.1880324","article-title":"Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain","volume":"22","author":"Taxonera","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"10.1016\/j.jval.2026.02.001_bib35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/ejhpharm-2018-001833","article-title":"Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain","volume":"27","author":"Trigo-Vicente","year":"2020","journal-title":"Eur J Hosp Pharm"},{"issue":"10","key":"10.1016\/j.jval.2026.02.001_bib36","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1365-2036.2008.03839.x","article-title":"A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis","volume":"28","author":"Tsai","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jval.2026.02.001_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.704889","article-title":"Cost-effectiveness analysis of vedolizumab compared with infliximab in anti-TNF-alpha-naive patients with moderate-to-severe ulcerative colitis in China","volume":"9","author":"Zhou","year":"2021","journal-title":"Front Public Health"},{"issue":"10","key":"10.1016\/j.jval.2026.02.001_bib38","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2026.02.001_bib40","series-title":"Pharmacoeconomic review report: vedolizumab (Entyvio - Takeda Canada Inc). Indication: ulcerative colitis [Internet]","year":"2015"},{"issue":"10","key":"10.1016\/j.jval.2026.02.001_bib41","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00535-019-01591-9","article-title":"Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey","volume":"54","author":"Naganuma","year":"2019","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jval.2026.02.001_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2024.1342656","article-title":"The efficacy of curcumin\/Qing Dai combination in children with active ulcerative colitis: a multicenter retrospective cohort study","volume":"12","author":"Nachum","year":"2024","journal-title":"Front Pediatr"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526000732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526000732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:02:59Z","timestamp":1782507779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526000732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1098301526000732"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.02.001","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Curcumin-QingDai Combination for Active Ulcerative Colitis: A Cost-Effectiveness Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}